Peripheral Nerve Block vs Spinal Anesthesia in Patients With Femur Fracture

November 24, 2023 updated by: Antonio Coviello, Federico II University

Peripheral Nerve Block vs Spinal Anesthesia in Patients With Femur Fracture: A Prospective Randomized Controlled Study

Femur Fractures (PF) are nowadays one of the main social and health problems in industrialized countries. PF are defined as crack or break of the proximal femur and they represent an important cause of morbidity and mortality in elderly population.

The main prospective and retrospective studies do not show the superiority of subarachnoid anesthesia over general anesthesia in terms of 30-day mortality and post-operative complications, however they always recommend the execution of PeripheralNerve Blocks (PNB). Loco-regional anesthesia plays a fundamental role in the treatment of peri-operative pain assuring better hemodynamic stability and has already fully entered national and international pain management protocols, because it allows faster recovery times with a reduction in the use of intravenous analgesic drugs in particular opioids and consequently a faster discharge and a reduction in peri-operative complications and the costs of assistance.

The aim of our study will be to propose an anesthetic approach based on PNB that could be particularly suitable for frail patients especially when Neuroaxial Anesthesia (NA) is not feasible due to difficulty to position the patient or to the withdrawal time of anticoagulant or antiplatelet therapies.

Study Overview

Detailed Description

A venous access (16-18 G) will be placed in the operating room and antibiotic prophylaxis will be administered (Cefazolin 1 or 2 gr. iv or, in case of allergy, Clindamycin 600 mg iv). Pantoprazole 40 mg iv will also be administered. Pulse oximetry (SpO2), heart rate (HR), body temperature (C°), continuous invasive blood pressure (cIBP), brain oximetry with ForeSight will be monitored. A co-loading with 500 ml of intravenous crystalloids will be done and ondansetron 4 mg will be administered intravenously; pre-procedural sedation will be performed with Midazolam 0.01-0.03 mg/Kg. All patients in both groups will receive intraoperative sedation with Dexmedetomidine 0.4-0.7 gamma/Kg/h and o2-therapy with a nasal cannula with a flow rate of 2L/min. At this point, the type of anesthesia will be followed on the basis of the randomization group.The following variables will be evaluated:

  • Postoperative pain evaluated by VAS and PAINAD scales
  • time to motor block regression (duration of motor block)
  • rate of side effects (nausea, vomiting and delirum)
  • rescue dose analgesics needed (interval between anesthesia and first rescue dose)
  • surgical compliance (obtained with a 5-point Likert scale score filled out by the surgeon)
  • duration of surgery

Study Type

Interventional

Enrollment (Estimated)

60

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Naples, Italy, 80131
        • Recruiting
        • University of Naples Federico II
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Older Adult

Accepts Healthy Volunteers

No

Description

"Inclusion Criteria" :

  • Subject has signed and dated an Informed Consent Form
  • Subject is classified as a ASA (American Society of Anesthesiologists) status I-IV
  • Subject is age over 65 years old
  • Subjects with femur fracture, candidates for intramedullary nailing surgery, to be operated on within 48 hoursPatients undergoing total hip arthroplasty

"Exclusion Criteria":

  • Age younger than 65 years
  • Subject with contraindications to subarachnoid technique or peripherical nerve blocks
  • Subject with local anesthetic allergy
  • Subject in whom the treatment protocol could not be fully applied were excluded from this study.
  • Study refusal
  • Neurological disease of the lower limbs

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Spinal Anesthesia
The participant will receive a spinal anesthesia.
Spinal anesthesia will be performed at the L2-L3 or L3-L4 interspace with the patients in the lateral position with the fractured side up. A small dose of local anesthetic will be injected into the skin at the planned site of insertion. More local anesthetic will be then administered along the intended path of the spinal needle insertion to the estimated depth of the supraspinous ligament. This serves a dual purpose: additional anesthesia for the spinal needle insertion and identification of the correct path for spinal needle placement. The technique will be performed aseptically in the subarachnoid space after observing clear Cephalo-Spinal Fluid (CSF) in the spinal needle 25 Gauge, and without releasing the CSF. Selected patients will be received Hypobaric Bupivacaine 0.5% 10 mg and Sufentanil 5 µg and will be maintained the lateral position for 15 min. At the end of these they will be gently placed in supine position.
The anesthesia mixtures were injected into the subarachnoid space for spinal anesthesia. It consisted of the following local anesthetics and adjuvants: Hypobaric Bupivacaine 0.5% 10 mg and Sufentanil 5 µg.
Active Comparator: Peripheral nerve block
The participant will receive a combination of femoral nerve block, sciatic nerve block with parasacral approach, lateral femoral cutaneous nerve block and obturator nerve block.

In this group, four nerve blocks will be associated to ensure adequate anesthesia and analgesia during surgery.

Sciatic nerve blocks with para sacral approach will be performed with a needle connected to an electrical nerve stimulation. The needle will be advanced until contraction of the related muscles. Next, an anesthetic solution of Ropivacaine 0.375% (dose 37.5 mg) plus Mepivacaine 1% (dose 100 mg) and Dexamethasone 4mg, total volume 21 ml, will be injected.

Lateral femoral cutaneous, femoral and obturator nerve blocks, femoral will be performed with the ultrasound technique. After identifying the nerves, a needle will be inserted with an "in plane" approach and will be injected.

The anesthesia mixture will consist for all of :Ropivacaine 0.375% (dose 9.375 mg) plus Mepivacaine 1% (dose 25 mg).

The volumes of the 3 anesthesia mixtures will be respectively: 1ml, 15ml,5ml.

The anesthesia mixtures were injected into selected peripheral nerves . It consisted of the following local anesthetics and adjuvants: Ropivacaine 0.375% plus Mepivacaine 1% and Dexamethasone 4 mg.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Postoperative pain evaluated by VAS scales
Time Frame: Every 6 hours during treatment until the first 24 postoperative hours
The VAS assessment will be done with a 10-cm-long line with verbal anchors at both ends ("no pain" on the far left and "the most intense pain" on the far right). The patient will mark a dot on the line corresponding to the pain intensity rating.
Every 6 hours during treatment until the first 24 postoperative hours
Postoperative pain evaluated by PAINAD scales
Time Frame: Every 6 hours during treatment until the first 24 postoperative hours
The PAINED scale (Pain Assessment in Advanced Dementia Scale) assesses 5 items: facial expression, breathing, negative vocalizations, consolability and body language with a range from 0 to 10 (1-3=mild pain; 4-6=moderate pain; 7-10=severe pain).
Every 6 hours during treatment until the first 24 postoperative hours

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Rate of postoperative nausea and vomiting (PONV)
Time Frame: Every 6 hours during treatment until the first 24 postoperative hours
We will analyze the risk factors of postoperative nausea and vomiting (PONV) by administering an Apfel score to each patient, practicing intraoperative and postoperative antiemetic treatment in accordance with the 2020 Fourth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting.
Every 6 hours during treatment until the first 24 postoperative hours
rescue dose analgesics needed
Time Frame: From the end of treatment to 24 hours postoperatively
interval between anesthesia and first rescue dose.Pharmacological therapy will be based on the patients' responses. After surgery, we will administer intravenous paracetamol 1 g 3 times a day. Ketorolac 30 mg (not for glomerular filtration rate < 50 ml/min) or Oxycodone (up to 0.1mg/Kg) mg will be available as rescue dose. Pain control will be considered good in case of VAS and PAINED score less than or equal to 4.
From the end of treatment to 24 hours postoperatively
surgical compliance
Time Frame: 1 hours after surgery
will be obtained with a 5-point Likert scale score filled out by the surgeon.
1 hours after surgery
The duration of surgery (min)
Time Frame: 4 hours after skin incision
The duration of surgery (min), assessed as Planned time(min) and Effective time(min)
4 hours after skin incision
Rate of Delirium
Time Frame: Every 6 hours during treatment until the first 24 postoperative hours
Postoperative delirium (POD) is an acute and fluctuating alteration of mental state of reduced awareness and disturbance of attention, which begins in the recovery room and occurs up to 5 days after surgery. POD will be detected by "3-Minute Diagnostic Confusion Assessment Method" (3D-CAM) and has four features: (1) altered mental status/fluctuating course, (2) inattention, (3) altered level of consciousness, and (4) disorganized thinking [27]. For the prevention and treatment of POD, we will follow the 2017 European Society of Anesthesiology guidelines.
Every 6 hours during treatment until the first 24 postoperative hours

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Time to motor block regression (duration of motor block)
Time Frame: Motor block was assessed immediately after the locoregional procedure, up to 24 hours postoperatively.
Time to motor block regression (duration of motor block), defined as the time between complete block (score 1) after T0 of local anesthetic injection and no motor block (score 4) on the Bromage scale (1, complete motor block, unable to move feet or knees; 2, almost complete motor block, able to move the feet only; 3, partial motor block, just able to move the knees; 4, none, full flexion of knees and feet;). Motor block will be evaluated before and 10, 15 and 20min after T0, and thereafter, every 30 minutes during surgery, and every hour in the postoperative period until its complete regression
Motor block was assessed immediately after the locoregional procedure, up to 24 hours postoperatively.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Antonio Coviello, Researcher, Federico II University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 1, 2023

Primary Completion (Estimated)

December 1, 2023

Study Completion (Estimated)

December 1, 2023

Study Registration Dates

First Submitted

July 2, 2023

First Submitted That Met QC Criteria

November 24, 2023

First Posted (Estimated)

December 5, 2023

Study Record Updates

Last Update Posted (Estimated)

December 5, 2023

Last Update Submitted That Met QC Criteria

November 24, 2023

Last Verified

November 1, 2023

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Spinal Anesthesia

Clinical Trials on Spinal anesthesia

3
Subscribe